Key result
A regimen of doxorubicin, vincristine, and cisplatinum yielded a 42% partial response rate in women with CMF-refractory breast cancer, but is not supported due to high toxicity.
Why the study?
Does monthly doxorubicin, vincristine, and cisplatinum improve response rates in women with advanced breast cancer refractory to CMF therapy?
Does monthly doxorubicin, vincristine, and cisplatinum improve response rates in women with advanced breast cancer refractory to CMF therapy?
The study does not support the use of cisplatinum in combination with doxorubicin and vincristine for CMF-refractory breast cancer due to toxicity and lack of sufficient efficacy.
Does not support use in CMF-refractory breast cancer; leaves open whether platinum combinations merit randomized evaluation.
Preliminary data suggesting synergistic activity of cisplatinum and doxorubicin and the expected poor prognosis of women with breast cancer who progress on treatment with cyclophosphamide, methotrexate and 5-fluorouracil (CMF), led to a trial of monthly doxorubicin (50 mg/M2), vincristine (1.4 mg/M2) and cisplatinum (50 mg/M2) in such patients. Overall partial response rate to this regimen was 42%; 37% progressed and 21% could not complete two cycles of therapy because of gastrointestinal (three or renal (one) toxicity. This study does not support the use of cisplatinum, 50 mg/M2, in combination with doxorubicin and vincristine in patients with breast cancer which has proven refractory to CMF therapy.
No takes yet. Share an insight, caveat, or question.
Trump et al. (1981) studied advanced breast cancer. doxorubicin, vincristine, and cisplatinum was evaluated on Overall partial response rate. A regimen of doxorubicin, vincristine, and cisplatinum yielded a 42% partial response rate in women with CMF-refractory breast cancer, but is not supported due to high toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: